Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BDSX
SellHot AirBiodesix, Inc. · Healthcare · United States · $283M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Biodesix, Inc. is a diagnostics company that develops and commercializes rapid, blood-based tests for lung cancer and other pulmonary diseases. The company's competitive advantage lies in its proprietary multi-omics platform and artificial intelligence, which deliver actionable clinical results within 72 hours, bypassing the need for invasive tissue biopsies. Biodesix operates as a high-growth niche player in the precision oncology space, supported by expanding Medicare coverage and clinical adoption.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.2M | 49.1M | 71.3M | 88.5M | 32.3% | 102.9M | 112.0M | 134.6M | 23.3% |
| EPS | -11.62 | -5.95 | -6.60 | -4.67 | — | -3.10 | -2.67 | -1.67 | — |
| Shares | 10.4M | 10.4M | 7.3M | 8.3M | -20.3% | 10.6M | — | — | — |
| Debt | 31.9M | 60.7M | 62.0M | 72.9M | 31.8% | 71.8M | — | — | — |
| Equity | 20.6M | 4.6M | 20.9M | -2.5M | 0.7% | — | — | — | — |
| Op CF | -45.0M | -22.9M | -48.6M | -23.3M | — | -19.8M | — | — | — |
| Inv CF | -3.5M | -23.1M | -3.4M | -0.4M | — | — | — | — | — |
| Fin CF | 58.9M | 29.1M | 52.0M | 16.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BDSX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BDSX | Biodesix, Inc.(you) | $283M | 29 | Sell |
| MYGN | Myriad Genetics, Inc. | $302M | 21 | Sell |
| XGN | Exagen Inc. | $179M | 28 | Sell |
| FLGT | Fulgent Genetics, Inc. | $540M | 45 | Hold |
| CSTL | Castle Biosciences, Inc. | $1.0B | 39 | Hold |
| OPK | OPKO Health, Inc. | $1.1B | 38 | Hold |
| 950200.KQ | Psomagen, Inc. | $50M | 24 | Sell |
| IMDX | Insight Molecular Diagnostics Inc. | $135M | 3 | Strong Sell |
| PSNL | Personalis, Inc. | $1.8B | 24 | Sell |
| 950130.KQ | Access Bio, Inc. | $65M | 13 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%